374 Participants Needed

Preventive Surgery for Ovarian Cancer

Recruiting at 8 trial locations
Age: 18 - 65
Sex: Female
Trial Phase: Academic
Sponsor: M.D. Anderson Cancer Center
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

What is the purpose of this trial?

This phase II trial studies how well surgery works in preventing ovarian cancer in patients with genetic mutations at risk of ovarian cancer. Risk reducing salpingo oophorectomy (RRSO) is surgery to remove the fallopian tubes and ovaries at the same time. Interval salpingectomy with delayed oophorectomy (ISDO) is surgery to remove the fallopian tubes. It is not known whether ISDO works better than RRSO at lowering risk of ovarian cancer and improving the sexual function and psychosocial well-being in patients with genetic mutation.

Will I have to stop taking my current medications?

The trial does not specify if you need to stop taking your current medications, but you cannot participate if you are currently being treated with Tamoxifen or Aromatase Inhibitors.

What data supports the effectiveness of the treatment Surgery for Preventive Surgery for Ovarian Cancer?

Research shows that proper surgical treatment can significantly improve survival rates for patients with advanced ovarian cancer, highlighting the importance of surgery in managing the disease.12345

Is preventive surgery for ovarian cancer generally safe for humans?

Surgery related to ovarian cancer screening has been shown to have a low rate of complications, with most being minor. In a study, 10% of patients experienced complications, mostly minor, and surgeries were generally well tolerated, even in repeat operations.678910

How does preventive surgery for ovarian cancer differ from other treatments?

Preventive surgery for ovarian cancer, specifically prophylactic oophorectomy or salpingo-oophorectomy, is unique because it involves the removal of the ovaries and/or fallopian tubes to significantly reduce the risk of developing ovarian cancer, especially in women with genetic risk factors like BRCA mutations. Unlike other treatments that focus on managing the disease after it occurs, this surgery is a preventive measure aimed at high-risk individuals to prevent cancer from developing in the first place.1112131415

Research Team

RN

Roni N Wilke, MD

Principal Investigator

M.D. Anderson Cancer Center

Eligibility Criteria

This trial is for premenopausal women with certain genetic mutations linked to a high risk of ovarian cancer. Participants must be willing to undergo surgery and follow-up care, not currently pregnant or within 3 months post-partum, have at least one fallopian tube and ovary, and cannot be on specific cancer medications.

Inclusion Criteria

Patients must understand that they will be permanently sterilized
I am a premenopausal woman with a genetic mutation linked to ovarian cancer.
I am willing to have two surgeries if I choose the ISDO treatment option.
See 4 more

Exclusion Criteria

I am currently taking tamoxifen or aromatase inhibitors.
My surgeon has deemed surgery too risky for me due to other health issues.
I am currently pregnant or have given birth in the last 3 months.
See 3 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Patients undergo either ISDO or RRSO surgery to prevent ovarian cancer

Surgery and immediate recovery

Follow-up

Participants are monitored for safety and effectiveness after treatment

2 years
Follow-up visits at 1 month, 6 months, 1 year, and 2 years

Treatment Details

Interventions

  • Surgery
Trial Overview The study compares two surgeries: Risk Reducing Salpingo-Oophorectomy (RRSO), which removes ovaries and fallopian tubes together; versus Interval Salpingectomy with Delayed Oophorectomy (ISDO), removing only the fallopian tubes first. It aims to find out which method better reduces cancer risk while preserving sexual function and well-being.
Participant Groups
2Treatment groups
Experimental Treatment
Active Control
Group I: Arm I (ISDO)Experimental Treatment4 Interventions
Patients undergo ISDO.
Group II: Arm II (RRSO)Active Control3 Interventions
Patients undergo RRSO.

Find a Clinic Near You

Who Is Running the Clinical Trial?

M.D. Anderson Cancer Center

Lead Sponsor

Trials
3,107
Recruited
1,813,000+

National Cancer Institute (NCI)

Collaborator

Trials
14,080
Recruited
41,180,000+

References

Impact of proper surgical treatment on the survival of patients with epithelial ovary cancer. [2023]
[Current treatment of malignant epithelial tumors of the ovary]. [2009]
Clinical course of patients treated for advanced ovarian carcinoma without surgical intervention. [2021]
[Management of malignant epithelial tumors of the ovary]. [2019]
Epithelial Ovarian Cancer-Varied Treatment Results. [2023]
Complications from Surgeries Related to Ovarian Cancer Screening. [2020]
Morbidity and mortality associated with primary and repeat operations for ovarian cancer. [2009]
Ovarian cancer surgery in Germany: An analysis of the nationwide hospital file 2005-2015. [2022]
Safety of fertility-sparing surgery in primary mucinous carcinoma of the ovary. [2021]
10.United Statespubmed.ncbi.nlm.nih.gov
Laparoscopic treatment of early ovarian cancer: surgical and survival outcomes. [2004]
11.United Statespubmed.ncbi.nlm.nih.gov
Prophylactic oophorectomy: clinical considerations. [2019]
12.United Statespubmed.ncbi.nlm.nih.gov
Ovarian Cancer Prevention in High-risk Women. [2023]
Prophylactic oophorectomy: why and when? [2019]
[Prophylactic surgery in common hereditary cancer syndromes]. [2013]
Opportunistic Salpingectomy as an Ovarian Cancer Primary Prevention Strategy. [2019]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security